Piramal Enterprises' Pharma Solution division, a global leader in contract development and manufacturing today said it plans to invest USD 40 million in new equipment and next generation technologies.
"To serve our partners better, Piramal Pharma Solutions continues to invest in next generation technologies and R&D. The recent investments include areas such as Anti-body Drug Conjugation (ADC), Advanced Flow Reactor (ARF) and Biocatalysis Centre of Excellence systems," a company statement said here.
In addition to the investment of USD 40 million in new equipment and technologies, the company will also augment related infrastructure, the release added.
Recently, the company completed a green field facility (USD 10 million) to double its Discovery Services capacity, and also approved a USD 20 million capacity expansion for Hormonal (Morpeth) and ADC (Grangemouth) manufacturing, the release said.
Piramal Pharma Solutions is an integrated solutions provider offering comprehensive range of services across the drug lifecycle. With a successful performance record of over four-decade in API supply (active pharmaceutical ingredients), drug products, drug discovery services, and with supply facilities in North America, Europe and Asia, it has established itself as a global market leader.
The company said it has secured four awards in three key categories of quality, reliability, and regulatory at the recent CMO Leadership Awards held in Boston, USA.
